Media coverage about Amyris (NASDAQ:AMRS) has trended somewhat positive this week, according to Accern. Accern rates the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Amyris earned a media sentiment score of 0.25 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.4076287493242 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the media stories that may have effected Accern’s rankings:
- Amyris, Inc. (AMRS) noted a price change of -0.30% and La Jolla Pharmaceutical Company (LJPC) closes with a move … – Stocks Gallery (stocksgallery.com)
- ETFs with exposure to Amyris, Inc. : October 12, 2017 (finance.yahoo.com)
- Amyris, Inc. (NASDAQ:AMRS) Short interest grew by 7.44 … – First News 24 (firstnewspaper24.com)
- Amyris (AMRS) Names Eduardo Alvarez COO (streetinsider.com)
- Amyris (AMRS) Names Eduardo Alvarez COO – StreetInsider.com (streetinsider.com)
AMRS has been the topic of a number of recent analyst reports. Zacks Investment Research lowered Amyris from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. HC Wainwright set a $15.00 target price on Amyris and gave the company a “buy” rating in a research report on Friday, August 11th. Cowen and Company set a $4.00 target price on Amyris and gave the company a “hold” rating in a research report on Thursday, August 17th. Finally, ValuEngine raised Amyris from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $20.69.
Amyris (NASDAQ:AMRS) last announced its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($1.41) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.06) by ($0.35). The firm had revenue of $25.68 million during the quarter, compared to the consensus estimate of $23.68 million. During the same quarter in the previous year, the firm earned ($0.06) earnings per share. The company’s quarterly revenue was up 167.5% compared to the same quarter last year.
WARNING: This article was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/2958169/amyris-amrs-earns-coverage-optimism-rating-of-0-25.html.
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with MarketBeat.com's FREE daily email newsletter.